265 related articles for article (PubMed ID: 36914766)
1. Chromogranin A-derived peptides pancreastatin and catestatin: emerging therapeutic target for diabetes.
Garg R; Agarwal A; Katekar R; Dadge S; Yadav S; Gayen JR
Amino Acids; 2023 May; 55(5):549-561. PubMed ID: 36914766
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity.
Bandyopadhyay GK; Mahata SK
Front Endocrinol (Lausanne); 2017; 8():20. PubMed ID: 28228748
[TBL] [Abstract][Full Text] [Related]
3. Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification.
Friese RS; Gayen JR; Mahapatra NR; Schmid-Schönbein GW; O'Connor DT; Mahata SK
Physiol Genomics; 2010 Feb; 40(3):195-207. PubMed ID: 19952279
[TBL] [Abstract][Full Text] [Related]
4. A common genetic variant of the chromogranin A-derived peptide catestatin is associated with atherogenesis and hypertension in a Japanese population.
Choi Y; Miura M; Nakata Y; Sugasawa T; Nissato S; Otsuki T; Sugawara J; Iemitsu M; Kawakami Y; Shimano H; Iijima Y; Tanaka K; Kuno S; Allu PK; Mahapatra NR; Maeda S; Takekoshi K
Endocr J; 2015; 62(9):797-804. PubMed ID: 26211667
[TBL] [Abstract][Full Text] [Related]
5. Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin.
Zhang K; Rao F; Wen G; Salem RM; Vaingankar S; Mahata M; Mahapatra NR; Lillie EO; Cadman PE; Friese RS; Hamilton BA; Hook VY; Mahata SK; Taupenot L; O'Connor DT
Diabetes Obes Metab; 2006 Nov; 8(6):621-33. PubMed ID: 17026486
[TBL] [Abstract][Full Text] [Related]
6. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome.
Bourebaba Y; Mularczyk M; Marycz K; Bourebaba L
Biomed Pharmacother; 2021 Feb; 134():111113. PubMed ID: 33341043
[TBL] [Abstract][Full Text] [Related]
7. Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling.
Bandyopadhyay GK; Vu CU; Gentile S; Lee H; Biswas N; Chi NW; O'Connor DT; Mahata SK
J Biol Chem; 2012 Jun; 287(27):23141-51. PubMed ID: 22535963
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)).
Biswas N; Curello E; O'Connor DT; Mahata SK
Cell Tissue Res; 2010 Dec; 342(3):353-61. PubMed ID: 21052719
[TBL] [Abstract][Full Text] [Related]
9. The immunomodulatory functions of chromogranin A-derived peptide pancreastatin.
Ioannidis M; Mahata SK; van den Bogaart G
Peptides; 2022 Dec; 158():170893. PubMed ID: 36244579
[TBL] [Abstract][Full Text] [Related]
10. Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance.
Bandyopadhyay GK; Lu M; Avolio E; Siddiqui JA; Gayen JR; Wollam J; Vu CU; Chi NW; O'Connor DT; Mahata SK
Diabetes; 2015 Jan; 64(1):104-16. PubMed ID: 25048197
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin.
Sánchez-Margalet V; González-Yanes C; Najib S; Santos-Alvarez J
Regul Pept; 2010 Apr; 161(1-3):8-14. PubMed ID: 20184923
[TBL] [Abstract][Full Text] [Related]
12. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo.
Fung MM; Salem RM; Mehtani P; Thomas B; Lu CF; Perez B; Rao F; Stridsberg M; Ziegler MG; Mahata SK; O'Connor DT
Clin Exp Hypertens; 2010; 32(5):278-87. PubMed ID: 20662728
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A regulates gut permeability via the antagonistic actions of its proteolytic peptides.
Muntjewerff EM; Tang K; Lutter L; Christoffersson G; Nicolasen MJT; Gao H; Katkar GD; Das S; Ter Beest M; Ying W; Ghosh P; El Aidy S; Oldenburg B; van den Bogaart G; Mahata SK
Acta Physiol (Oxf); 2021 Jun; 232(2):e13655. PubMed ID: 33783968
[TBL] [Abstract][Full Text] [Related]
14. Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits.
Sahu BS; Obbineni JM; Sahu G; Allu PK; Subramanian L; Sonawane PJ; Singh PK; Sasi BK; Senapati S; Maji SK; Bera AK; Gomathi BS; Mullasari AS; Mahapatra NR
J Biol Chem; 2012 Dec; 287(52):43840-52. PubMed ID: 23105094
[TBL] [Abstract][Full Text] [Related]
15. Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity.
Ying W; Mahata S; Bandyopadhyay GK; Zhou Z; Wollam J; Vu J; Mayoral R; Chi NW; Webster NJG; Corti A; Mahata SK
Diabetes; 2018 May; 67(5):841-848. PubMed ID: 29432123
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.
Watanabe T
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204153
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.
Mahata SK; Corti A
Ann N Y Acad Sci; 2019 Nov; 1455(1):34-58. PubMed ID: 31588572
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment.
Dev NB; Gayen JR; O'Connor DT; Mahata SK
Endocrinology; 2010 Jun; 151(6):2760-8. PubMed ID: 20410203
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A and derived peptides in health and disease.
Loh YP; Cheng Y; Mahata SK; Corti A; Tota B
J Mol Neurosci; 2012 Oct; 48(2):347-56. PubMed ID: 22388654
[TBL] [Abstract][Full Text] [Related]
20. Pancreastatin inhibitor PSTi8 protects the obesity associated skeletal muscle insulin resistance in diet induced streptozotocin-treated diabetic mice.
Gupta AP; Garg R; Singh P; Goand UK; Syed AA; Valicherla GR; Riyazuddin M; Mugale MN; Gayen JR
Eur J Pharmacol; 2020 Aug; 881():173204. PubMed ID: 32439261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
